To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Resource Library
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Our Investigational Pipeline
Commitment to evolving the research landscape
Our pipeline starts with strong science that is aimed at translating immunology breakthroughs into differentiated medicines.
argenx researches investigational therapies for rare diseases for underserved populations.
The agents below are not approved for the uses listed by any regulatory agency as efficacy and safety have not been established.
Pipeline Resources
Disclaimer
These resources contain information for healthcare providers and is intended solely for educational purposes. This display includes ongoing clinical trials for investigational compounds. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Information about all trials can be found at www.clinicaltrials.gov.
Empasiprubart MoA Video
ARGX-119 MoA Video
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx.
© 2025 argenx MED-US-NON-2400036 V4 11/2025. All Rights Reserved.